MedTrace Logo

Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain

NCT05674240 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-03-27

No results posted yet for this study

Summary

This Registry study will prospectively evaluate the differences in treatment outcomes in terms of pain intensity, pain interference, concomitant medication use, health-related quality of life, opioid adverse effects, and healthcare utilization between targeted drug delivery and conservative medication management only groups.

Conditions

  • Cancer Pain
  • Chronic Pain
  • Cancer Associated Pain
  • Neuropathic Pain

Interventions

DEVICE

Intrathecal Targeted Drug Delivery

Intrathecal drug delivery systems (IDDs) deliver small doses of analgesics directly to the spinal cord.

COMBINATION_PRODUCT

Conservative medical management

Including physical therapy, oral or transdermal medications and injections

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Lauren Littlefield, MD · Wake Forest University Health Sciences

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-06
Primary Completion
2026-03-20
Completion
2026-03-20
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05674240 on ClinicalTrials.gov